Moderna (NASDAQ:MRNA) Now Covered by Analysts at Berenberg Bank

Berenberg Bank began coverage on shares of Moderna (NASDAQ:MRNA) in a report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “hold” rating and a $42.00 price target on the stock. Berenberg Bank’s target price would indicate a potential upside of 13.70% from the company’s previous close.

A number of other research analysts have also issued reports on the company. Bank of America reduced their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday. Finally, TD Cowen reduced their price target on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $84.00.

Moderna Trading Down 0.9 %

MRNA opened at $36.94 on Tuesday. The firm’s fifty day moving average price is $56.98 and its 200 day moving average price is $95.46. The stock has a market capitalization of $14.22 billion, a PE ratio of -6.35 and a beta of 1.69. Moderna has a 12-month low of $35.80 and a 12-month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the company posted ($1.39) earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. As a group, research analysts expect that Moderna will post -9.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 13.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 2,930 shares of company stock valued at $217,170. 15.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Commerzbank Aktiengesellschaft FI lifted its stake in shares of Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the last quarter. CVA Family Office LLC boosted its holdings in Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC grew its position in shares of Moderna by 2.0% in the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after purchasing an additional 108 shares during the last quarter. McAdam LLC increased its stake in shares of Moderna by 1.1% in the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after purchasing an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC boosted its stake in Moderna by 1.1% during the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock valued at $1,826,000 after purchasing an additional 160 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.